Minato-ku, Japan

Atsuhiro Abe


 

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 31(Granted Patents)


Location History:

  • Tokyo, JP (2000 - 2009)
  • Minato-ku, JP (2013)

Company Filing History:


Years Active: 2000-2013

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Atsuhiro Abe: Innovator in Pharmaceutical Chemistry

Introduction

Atsuhiro Abe is a prominent inventor based in Minato-ku, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 5 patents. His work focuses on developing novel compounds and methods that enhance drug efficacy and safety.

Latest Patents

Abe's latest patents include a γ-secretase inhibitor, which aims to provide a novel compound with an excellent γ-secretase inhibitory effect that specifically inhibits Aβ production. This invention presents a compound formula that includes various alkyl and phenyl groups, showcasing his innovative approach to drug design. Another notable patent is a method for preparing polymorphism of irinotecan hydrochloride. This method results in a novel crystalline polymorphic form that exhibits excellent solubility in water and reduced impurities. The preparation involves mixing irinotecan with selected solvents and hydrochloric acid to collect the formed crystals.

Career Highlights

Throughout his career, Atsuhiro Abe has worked with notable companies such as Kabushiki Kaisha Yakult Honsha and Sony Group Corporation. His experience in these organizations has contributed to his expertise in pharmaceutical development and innovation.

Collaborations

Abe has collaborated with esteemed colleagues, including Hideaki Shimizu and Seigo Sawada. These partnerships have further enriched his research and development efforts in the pharmaceutical industry.

Conclusion

Atsuhiro Abe's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his role as a key inventor in the field. His work continues to influence the development of effective therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…